{"id":95245,"date":"2026-05-23T23:36:09","date_gmt":"2026-05-23T23:36:09","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/95245\/"},"modified":"2026-05-23T23:36:09","modified_gmt":"2026-05-23T23:36:09","slug":"nova-era-lecby-obezity-prvni-tabletka-na-hubnuti-dostala-zelenou-jak-se-uziva","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/95245\/","title":{"rendered":"Nov\u00e1 \u00e9ra l\u00e9\u010dby obezity: Prvn\u00ed tabletka na hubnut\u00ed dostala zelenou. Jak se u\u017e\u00edv\u00e1?"},"content":{"rendered":"<p>Lid\u00e9, kte\u0159\u00ed hubnou za pomoci agonist\u016f GLP-1, si u\u017e nov\u011b nebudou muset p\u00edchat injekce. Evropsk\u00e1 l\u00e9kov\u00e1 agentura <a href=\"https:\/\/www.ema.europa.eu\/en\/news\/first-oral-glp-1-treatment-weight-management\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">schv\u00e1lila<\/a> tablety Wegovy, kter\u00e9 m\u011bly v\u00a0klinick\u00e9 studii stejn\u00e9 v\u00fdsledky jako injekce. Komu hork\u00e1 novinka pom\u016f\u017ee a jak\u00e9 podm\u00ednky se p\u0159i jej\u00edm u\u017e\u00edv\u00e1n\u00ed dodr\u017euj\u00ed?<\/p>\n<p>Evropsk\u00e1 l\u00e9kov\u00e1 agentura schv\u00e1lila prvn\u00ed tabletku na hubnut\u00ed typu agonist\u016f GLP-1. Wegovy (semaglutid) lze u\u017e\u00edvat spolu s dietou a fyzickou aktivitou u dosp\u011bl\u00fdch s obezitou nebo nadv\u00e1hou, kte\u0159\u00ed maj\u00ed alespo\u0148 jednu komorbiditu souvisej\u00edc\u00ed s hmotnost\u00ed. Tedy nap\u0159\u00edklad diabetes 2. typu, hypertenzi, vysok\u00fd cholesterol, kardiovaskul\u00e1rn\u00ed onemocn\u011bn\u00ed nebo obstruk\u010dn\u00ed sp\u00e1nkov\u00e1 apnoi.<\/p>\n<p>Tablety Wegovy p\u016fjde z\u00edskat pouze na l\u00e9ka\u0159sk\u00fd p\u0159edpis. L\u00e9k se u\u017e\u00edv\u00e1 jednou denn\u011b nala\u010dno, po alespo\u0148 8 hodin\u00e1ch bez j\u00eddla. Pacienti by pak m\u011bli po\u010dkat 30 minut, ne\u017e se naj\u00ed, napij\u00ed nebo u\u017eij\u00ed jin\u00e9 l\u00e9ky. Tablety nab\u00edzej\u00ed peror\u00e1ln\u00ed alternativu k t\u00fddenn\u00edm subkut\u00e1nn\u00edm injekc\u00edm. A\u010dkoli maj\u00ed subkut\u00e1nn\u00ed injekce Wegovy schv\u00e1len\u00ed pro pacienty od 12 let, tablety mohou u\u017e\u00edvat jen dosp\u011bl\u00ed.<\/p>\n<p>T\u0159i \u010dtvrtiny lid\u00ed zhubly<\/p>\n<p>Bezpe\u010dnost a \u00fa\u010dinnost tablet Wegovy se testovala v klinick\u00e9 studii f\u00e1ze 3, kter\u00e9 se \u00fa\u010dastnilo 307 dosp\u011bl\u00fdch s obezitou nebo nadv\u00e1hou a alespo\u0148 jednou komorbiditou. Lid\u00e9 u\u017e\u00edvali Wegovy nebo placebo spolu s n\u00edzkokalorickou dietou a zv\u00fd\u0161enou fyzickou aktivitou po dobu 64 t\u00fddn\u016f. Prim\u00e1rn\u00edmi c\u00edlov\u00fdmi parametry byla zm\u011bna t\u011blesn\u00e9 hmotnosti oproti v\u00fdchoz\u00edmu stavu a pod\u00edl \u00fa\u010dastn\u00edk\u016f, kte\u0159\u00ed na konci l\u00e9\u010dby zhubli alespo\u0148 5 % sv\u00e9 t\u011blesn\u00e9 hmotnosti.<\/p>\n<p>Lid\u00e9, kte\u0159\u00ed u\u017e\u00edvali tablety Wegovy, zhubli v pr\u016fm\u011bru 13,61 % sv\u00e9 t\u011blesn\u00e9 hmotnosti ve srovn\u00e1n\u00ed s 2,18 % ve skupin\u011b s placebem. Krom\u011b toho 76,3 % lid\u00ed u\u017e\u00edvaj\u00edc\u00edch tablety Wegovy zhublo alespo\u0148 5 % sv\u00e9 t\u011blesn\u00e9 hmotnosti ve srovn\u00e1n\u00ed s 30,5 % pacient\u016f u\u017e\u00edvaj\u00edc\u00edch placebo.<\/p>\n<p>K nej\u010dast\u011bj\u0161\u00edm ne\u017e\u00e1douc\u00edm \u00fa\u010dink\u016fm tablet pat\u0159ily gastrointestin\u00e1ln\u00ed pot\u00ed\u017ee, v\u010detn\u011b nevolnosti, pr\u016fjmu, z\u00e1cpy, bolesti b\u0159icha, dyspepsie a zvracen\u00ed. Tyto ne\u017e\u00e1douc\u00ed \u00fa\u010dinky se vyskytovaly hlavn\u011b na za\u010d\u00e1tku l\u00e9\u010dby. Bezpe\u010dnostn\u00ed profil denn\u00edch tablet Wegovy byl podobn\u00fd t\u00fddenn\u00edm injekc\u00edm Wegovy.<\/p>\n","protected":false},"excerpt":{"rendered":"Lid\u00e9, kte\u0159\u00ed hubnou za pomoci agonist\u016f GLP-1, si u\u017e nov\u011b nebudou muset p\u00edchat injekce. Evropsk\u00e1 l\u00e9kov\u00e1 agentura schv\u00e1lila&hellip;\n","protected":false},"author":2,"featured_media":95246,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[12],"tags":[67,68,1614,14811,28781,5294,28782],"class_list":["post-95245","post","type-post","status-publish","format-standard","has-post-thumbnail","category-byznys","tag-business","tag-byznys","tag-ema","tag-glp-1","tag-nove-leky","tag-obezita","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116626521053869443","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/95245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=95245"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/95245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/95246"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=95245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=95245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=95245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}